NEW YORK (GenomeWeb) – Definiens announced today that Takeda Pharmaceuticals will use its new cloud-based digital pathology platform in its translational and biomarker research.

When combined with deeply researched biomarker analysis, Definiens said its new platform, VeriTrova, can help translate biomarker research into the clinic through a new generation of diagnostics. Takeda, an early adopter of the platform, plans to use it for comprehensive tissue-based analysis in its clinical trials, and to support its clinical biomarker development programs.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.